Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Oct 14 - Oct 19
Today, these states remain unlikely to centralize in the way Washington imagines
Drug Discovery Today , 20 (1), 122128
Andrea Corona Altimmunes GLP-1 drug shows positive results for alcohol use disorder On Tuesday, Altimmune announced topline data from their Phase 2 RECLAIM trial showing that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced the number of heavy drinking days compared to placebo in patients with moderate to severe alcohol use disorder
Peptide-driven approaches in advanced wound healing materials
In human cosmetic studies, measurable changes in skin firmness, fine lines, or density have been reported from 4 weeks onward with consistent daily topical use
US$ 23.53
US$ 28.17
US$ 24.80
US$ 25.22
US$ 23.63
